Harnessing immunotherapy to revolutionise antifungal treatment
At mycoBiologics, we are pioneering a new era in the fight against life-threatening fungal infections.
Our innovative approach leverages patient-derived human monoclonal antibodies (mAbs) to create a novel class of antifungal therapies.
Designed to combat critical Candida infections in hospitalized patients, our treatment offers a paradigm shift from traditional antifungals—harnessing the body’s natural immune defences to precisely target and eliminate infections.
